Heptares Therapeutics Limited

Heptares Therapeutics Limited

GPCR drug discovery & development

Heptares was acquired by Sosei in 2015 for an initial cash consideration of USD 180 million and further milestone payments of up to USD 220 million. The transaction provides Sosei with world-class technology platform and clinical pipeline targeting G protein-coupled receptors (GPCRs).

Contact Name
Dr. Malcolm Weir

Company Position
Chief Executive Officer

Contact Address
BioPark
Broadwater Road
Welwyn Garden City
Hertfordshire
AL7 3AX
UK